- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01141855
Smoking Termination Opportunity for inPatients (STOP)
Effectiveness of Inpatient Initiated Varenicline Tartrate for Smoking Cessation, for Smoking Related Illnesses.
The Smoking Termination Opportunity for inPatients, (STOP) project is designed to capture the opportunity that is provided by admission for acute smoking related illness, to assist patients through withdrawal by use of a combination of:
- the new medication Champix with
- best practice counselling
- initiated in an inpatient setting
to achieve:
- sustained smoking abstinence
- reduced hospital bed and health service utilisation
- reduced inpatient smoking and craving prior to discharge
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
A national standard in public hospitals for the management of smoking in patients admitted with smoking related acute illnesses is lacking. Where such patients have continued to smoke up until the time of admission, it can be assumed that "primary" prevention has failed.
Once admitted, there is a vastly under-utilised opportunity, by use of a structured and systematic approach, to intervene with a secondary prevention attempt. This takes advantage of the synergy of:
- the smoker is a "captive audience" and may be receptive to considering lifestyle factors that have lead to the admission, and
- best practice medication and counselling can be initiated prior to discharge. If proven to be cost-effective in our analysis, a systematic roll-out of this secondary prevention initiative would be advocated. ie translation of research into practice.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
Adelaide, South Australia, Australia, 5011
- The Queen Elizabeth Hospital
-
Adelaide, South Australia, Australia, 5112
- Lyell McEwin Health Service
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Smoker of at least 10 cigarettes per day on average over the past 12 months
- Inpatient with an anticipation admission of at least one day
- Willingness to quit smoking
- Aged between 20 and 75 years
- A plan of discharge to go home
- Acute hospital admission with cardiovascular, cerebrovascular, peripheral vascular diseases or airways (asthma and/or Chronic Obstructive Pulmonary disease
Exclusion Criteria:
- Subject preference to use an alternative pharmacotherapy for smoking cessation
- Respiratory patient being considered for home oxygen
- Pregnancy
- Breast feeding
- Acute or pre-existing severe psychiatric illnesses
- Past history of psychosis or suicidal ideation
- Renal impairment with creatinine clearance <30ml/min
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Champix plus counselling
varenicline tartrate will be initiated whilst subjects are inpatients with the standard MIMS dosing schedule (including period of titration).
In combination with Quit SA (5A) telephone counselling service
|
Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days 1mb b.d. for 70 days (full course 3 months)
Altri nomi:
|
|
Comparatore attivo: counselling alone
5A counselling via Quit SA (quitline) telephone counselling service.
(maximum 8 phone calls per subject within a 3 month period).
|
Quit SA 5A counselling over the phone.
Maximum 8 calls over a 3 month period
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Smoking abstinence
Lasso di tempo: one year
|
Continued smoking abstinence is defined as: less than or equal to no more than 5 cigarettes smoked during the period of 2 weeks to 12 months post enrollment.
|
one year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Reduced hospital bed utilisation
Lasso di tempo: one year
|
Hospital casemix/DRG data will be collected for the 5 years prior to enrollment and one year post enrollment.
This will be supplemented by SA Department of Health data and PBS/MBS data sets of study completion, to monitor admissions at other hospitals and GP visits.
|
one year
|
|
7-day point prevalence
Lasso di tempo: from 2 weeks to 3 months post enrollment
|
Defined as no cigarettes for the previous 7 days
|
from 2 weeks to 3 months post enrollment
|
|
Reduction in health care costs
Lasso di tempo: one year
|
Reduced health care costs with greater economic value will be relative to other health interventions.
Four seperate economic models will be built for vascular diseases: cardiovascular, cerebrovascular and peripheral vascular diseases and airways diseases: asthma and/or chronic obstructive pulmonary disease.
Each model will compare outcomes and costs for varenicline and counselling compared to counselling alone, and will incorporate epidemiological data on natural disease progression of smokers and previous smokers from the four disease profiles split by gender if indicated.
|
one year
|
|
Inpatient craving levels
Lasso di tempo: baseline to end of inpatient stay
|
Craving scales will be used to assess levels during inpatient stay (pre and post intervention delivery)
|
baseline to end of inpatient stay
|
|
Prevalence of inpatient smoking
Lasso di tempo: From baseline to end of inpatient stay
|
Measured by self-report and observation by hospital and study staff prior to discharge.
|
From baseline to end of inpatient stay
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Brian J Smith, MBBS; FRACP;PhD;Dip Clin Epid, The Queen Elizabeth Hospital
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 2008012
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .